Lepu Biopharma FY26 H1 profit falls 15.2% to RMB 24.8 million; revenue rises 12.1% to RMB 522.4 millionPUBT·2 days ago, 03:39 AM02157-6.73%
Lepu Biopharma sets board meeting to review interim results, consider dividendPUBT·Aug 7 at 06:06 AM02157-6.73%
Lepu Biopharma says Phase III CLARITY-Gastric01 trial meets overall survival endpoint for CMG901 in late-line gastric cancerPUBT·Jul 27 at 11:28 PM02157-6.73%
Lepu Biopharma names Ren Fangyuan employee representative supervisor, replacing Zhao LixuanPUBT·Jul 15 at 03:49 AM02157-6.73%
HK Semiconductor Sector Retreats as Fullhan Microelectronics Posts 1.69B Yuan RevenueGlobal Report·Jul 3 at 06:34 AM02157-6.73%
Lepu Biopharma Exits Biotech Marker Regime After Meeting HKEX Mainboard TestsTip Ranks·May 6 at 07:39 AM02157-6.73%
